Evolus Reports Q4 Revenue of $90.3M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Should l Buy EOLS?
Reports Q4 revevnuee $90.3M, consensus $89.58M. "In 2025 we generated nearly $300 million in total net revenue delivering our sixth consecutive year of double-digit growth," said David Moatazedi, President and Chief Executive Officer of Evolus. "Our performance beauty positioning supported by clinically differentiated products has enabled us to continue to outpace the market while strengthening U.S. and International share for Jeuveau and successfully expanding our U.S. injectable portfolio with the launch of Evolysse. The consistency of our relative outperformance reflects the durability of our commercial model and the growing relevance of our portfolio to today's aesthetic consumer."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.290
Low
18.00
Averages
19.25
High
20.00
Current: 4.290
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
See More
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
See More
